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Abstract
Qualitative characteristics of cytotoxic CD8+ T cells (CTLs) are important in measuring the effectiveness of CTLs in controlling
HIV-1 infections. Indeed, in recent studies patients who are naturally resistant to HIV-1 infections have been shown to
possess CTLs that are of high functional avidity and have a high capacity to recognize HIV epitope variants, when compared
to HIV-1 infection progressors. When developing efficacious vaccines, assays that can effectively measure CTL quality
specifically in vivo are becoming increasingly important. Here we report the use of a recently developed high-throughput
multi-parameter technique, known as the fluorescent target array (FTA) assay, to simultaneously measure CTL killing
magnitude, functional avidity and epitope variant cross-reactivity in real time in vivo. In the current study we have applied
the FTA assay as a screening tool to assess a large cohort of over 20 different HIV-1 poxvirus vaccination strategies in mice.
This screen revealed that heterologous poxvirus prime-boost vaccination regimes (i.e., recombinant fowlpox (FPV)-HIV
prime followed by a recombinant vaccinia virus (VV)-HIV booster) were the most effective in generating high quality CTL
responses in vivo. In conclusion, we have demonstrated how the FTA assay can be utilized as a cost effective screening tool
(by reducing the required number of animals by .100 fold), to evaluate a large range of HIV-1 vaccination strategies in
terms of CTL avidity and variant cross-reactivity in an in vivo setting.
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Introduction
Since the discovery of HIV as the causative agent for AIDS in
1983, the search for an effective vaccination strategy to control
global HIV-1 progression has generated many promising yet
disappointing outcomes [1–4]. Notable immune correlates in ‘elite
controllers’ of HIV-1, however, may give clues as to what
parameters should be targeted in rational vaccine design. In
particular the presence of CTLs with high functional avidity and
broad epitope variant cross-reactivity has been associated with
HIV-1 control in elite controllers [5–7]. It is postulated that these
CTL parameters could be a hallmark of effectively controlling
HIV-1 infection.
Many of the current assays used to predict the efficacy of T cell
immunity following vaccination provide limited insight with
regards to functional avidity and epitope variant cross-reactivity.
Moreover, currently available in vivo-based T cell function assays
have limited capacity to effectively measure both functional avidity
and epitope variant cross-reactivity [8–10]. Hence, we have
recently developed a high-throughput multi-parameter in vivo T
cell assay using the FTA technology that has the ability to measure
functional avidity and epitope variant cross-reactivity with greater
efficiency [11,12]. This technique involves labeling of leukocyte
target cells with carboxyfluorescein succinimidyl ester (CFSE), Cell
Trace Violet (CTV) and Cell Proliferation Dye eFluor670 (CPD)
to generate over 250 unique target cell clusters that can be injected
into animals to monitor T cell responses in real time in vivo. This
technique allows for the measurement of parameters such as
cumulative magnitude of killing, functional avidity and epitope
variant cross-reactivity of CTLs responding against FTA targets
pulsed with peptides that bind to major histocompatibility complex
(MHC) class I (MHC-I) molecules. In addition, the FTA assay also
allows CD4+ T helper (TH) cell activity to be measured based on
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the ability of TH cells to activate (e.g., up-regulate CD69
expression) FTA B cells pulsed with MHC class II (MHC-II)
binding peptides.
In previous studies Ranasinghe et al have established that the
combination of vaccine route and the order in which HIV-1 pox
viral vaccine vectors are delivered in a prime-boost vaccination
strategy, can alter magnitude and also the quality of HIV-specific
CTL immunity [13–15]. In the current study the FTA assay was
used to further clarify which pox-viral vector combination induced
the best T cell immune outcome in terms of cumulative
magnitude, functional avidity and epitope variant cross-reactivity
of T cell responses in vivo following HIV-1 poxvirus prime-boost
vaccination. The primary aim of the current study was to test the
feasibility of using the FTA assay as a high-throughput vaccine
screening tool to measure vaccine efficacy in animal models with
the hope of establishing the best HIV-1 prime-boost vaccine vector
combination that has potential to succeed into pre-clinical
evaluation.
Results
Utility of the FTA assay in measuring T cell responses in
vivo
To establish the utility of the FTA assay, six BALB/c mice were
immunized with wild-type vaccinia virus (VV) and in vivo killing
responses to VV epitopes were assessed using the assay. Responses
were assessed against the VV CTL epitopes F2L, the VV
dominant epitope, F2L mut, a variant of F2L derived from
modified vaccinia Ankara virus, and A52R, a subdominant VV
epitope. A schematic representation of the steps involved in this
technique is depicted in Figure 1. As anticipated, greatest CTL
killing was observed against targets pulsed with immunodominant
F2L, followed by responses to the subdominant epitope A52R
(Fig. 2a and 2b). Despite not being present in the VV used for
infection, the F2L mut epitope was also recognized by CTLs in
infected animals demonstrating an epitope variant cross-reactive
response (Fig. 2a and Fig. 2b). CTL responses were not
detected against targets pulsed with the control HIV neg epitope,
which is also not expressed by wild-type VV (Fig. 2a and 2b).
These trends can be summarized by measuring the area under
each curve (AUC) of the killing response, an indicator of the
overall magnitude of CTL killing (Fig. 2c). In addition, the
functional avidity of the CTL killing response was determined by
calculating the effective concentration of peptide used to pulse the
target cells required to generate half maximal killing (EC50)
(Fig. 2d). This revealed that CTLs required 10 times the amount
of A52R peptide to generate half maximal killing compared to F2L
(Fig. 2d). Epitope variant cross-reacting CTLs required 70 fold
higher amounts of F2L mut peptide than F2L to generate half
maximal killing (Fig. 2d). These data provide an example of the
utility of the FTA assay in measuring effector T cell response
magnitude, functional avidity and epitope variant cross-reactivity
in individual animals and highlights its reproducibility.
Screening of VV- and FPV–based prime-boost vaccine
regimes using the FTA assay
Having established the utility of the FTA assay, we applied the
technique to screen for various HIV-1 poxvirus prime-boost
vaccination regimes for their ability to induce CTL and TH cell
responses. To assess this we generated a vaccine regime matrix
based on all the combinations (i.e., 24 combinations) of two vectors
fowl pox virus (FPV)-HIV and VV-HIV given either i.n. or i.m. as
a single vaccination or prime-boost strategy (Table 1). Immune
responses to 7 different T cell epitopes were investigated, including
two vaccinia CTL epitopes (F2L, F2L mut) as positive controls for
robust CTL responses and four HIV CTL epitopes (HIV Gag,
HIV Pol, HIV Env and HIV Gag mut, a HIV Gag subtype C
variant of HIV Gag [25] not present in the vaccines and included
to assess for epitope variant cross-reactive responses). Also a HIV
Gag MHC-II binding epitope known as Gag TH, which we have
previously shown to allow activation of B cell targets, was also
included to measure TH cell responses [12].
Splenocytes from mice vaccinated using the various regimes
described in Table 1 were assessed for FTA cell death and B cell
activation to measure CTL activity and TH responses respectively
(See Figure 1c for TH response assessment). A representative result
from three independent experiments is shown in Figure S1a, b,
c, d, and e and includes data from six intra-animal replicates
totaling 6048 data points per experiment. Due to the large amount
of data generated in this instance, AUC values were calculated for
responses against each epitope and this depicted as a heat map to
allow trends to be clearly revealed (Fig. 3a). From the heat map it
was clear that several vaccine regimes gave killing responses to the
HIV Gag epitope and even the HIV Gag mut epitope,
approaching those generated to F2L mut in VV vaccine regimes.
In contrast, negligible killing responses to HIV Pol and HIV Env
epitopes were present. Furthermore, there were also several
vaccine strategies that gave robust TH cell responses to the Gag
TH epitope. Focusing on the three HIV Gag epitopes revealed two
notable clusters of vaccine regimes giving high magnitude T cell
responses, which corresponded to heterologous poxvirus prime-
boost vaccine strategies (Fig. 3b highlighted in red and
green). Of particular note was a cluster of four heterologous
prime-boost vaccine regimes comprised of FPV-HIV prime and
followed by VV-HIV booster vaccination (Fig. 3b highlighted
in red). These vaccine strategies elicited high magnitude killing of
targets presenting the HIV Gag epitope, and similarly the HIV
Gag mut epitope. These responses were indicative of robust Gag
epitope variant cross-reactive CTL responses following vaccina-
tion.
The functional avidity analysis of the responses to the two CTL
HIV Gag epitopes revealed that the FPV-HIV/VV-HIV prime-
boost immunization cluster also generated CTL responses of
greatest avidity as these regimes showed the lowest EC50 killing
responses compared to other vaccination regimes tested (Fig. 3c).
No route dependent differences were detected in this cluster. The
second notable cluster in terms of generating high quality CTL
responses was that of two heterologous vaccine strategies
comprised of VV-HIV prime followed by i.m. FPV-HIV booster
vaccination (Fig. 3b highlighted in green and 3c). While
these two clusters of heterologous prime-boost vaccination regimes
also generated TH cell responses to the Gag TH epitope, negligible
avidity changes were apparent with these MHC-II-restricted TH
cell responses (Fig.3b and 3c). Thus, overall the best vector
combination in terms of inducing high quality CTL cell responses
was found to be heterologous prime-boost vaccination regimes.
Once vaccine strategies of interest have been identified from
these heat map summary statistics, detailed analysis can be
performed on particular vaccine regimes of interest. For example,
from previous studies [13–16] the i.n. FPV-HIV/i.m. VV-HIV
prime-boost vaccination strategy seemed particularly promising in
generating HIV-specific CD8+ T-cells responses; and this was also
found to be an outstanding regime in his study being in the FPV-
HIV/VV-HIV prime-boost cluster. Therefore, detailed analysis of
this prime-boost regime relative to the prime and boost vaccine
components alone was performed. Although FPV-HIV alone
vaccination induced negligible CTL responses against the 3 Gag
epitopes (Fig. 4), the recombinant VV-HIV alone typically
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generated a good killing response to Gag, a low killing response to
Gag mut and a low TH response to Gag Th (Fig. 4). Despite
generating negligible responses to the Gag epitopes, FPV
vaccination dramatically improved Gag specific killing responses
when given as a prime vaccination with a VV boost vaccination.
The killing response to Gag pulsed targets increased to levels on a
par with targets pulsed with F2L mut epitopes (Fig. 4a and 4c).
Furthermore, there was a 9-fold functional avidity improvement
against the Gag epitope in the prime-boost animals compared to
vaccination with VV alone (Fig. 4c). What was also striking was
the dramatic increase in response to the Gag mut epitope in the
animals given the prime-boost regime both in terms of magnitude
and functional avidity, with a 3-fold increase in cumulative killing
and a 42-fold functional avidity improvement compared to
responses generated to VV alone (Fig. 4c). There was also a 4-
fold increase in cumulative T helper response towards the Gag Th
epitope in these animals; although there was no detectable
functional avidity change in the Gag Th response (Fig. 4d). This
detailed analysis revealed that despite not generating a detectable
immune response when given alone, FPV-HIV vaccination could
dramatically influence the magnitude, functional avidity and cross-
reactivity when used in a FPV-HIV/VV-HIV modality.
Refinement of in vivo T-cell assays using FTA technology
dramatically reduces the numbers of animal required for
screening vaccine-induced T-cell responses
By using the 252-parameter FTA assay described here, the
number of animals required to assess T-cell responses in vivo were
dramatically reduced. This is highlighted in the vaccine screening
experiment above. If 25 vaccine strategies (including a naı¨ve
control and 24 vaccinations) were assessed using a conventional 2-
parameter in vivo CTL assay, against 7 distinct epitopes at 6
epitope concentrations and 6 replicates, the total number of host
mice required would equal 6300 (Table 2). To perform this study
using this number of animals, a limit of 50 animals per experiment
might be achievable considering the number of events required
during flow cytometry; and therefore a projected number of 126
experiments would have to be performed. Each of these
experiments would use one additional animal (minimum) as a
donor for target cells. Therefore, a total number of 6426 animals
might be needed to perform the entire vaccine screen study over
126 experiments using a 2-parameter assay. This contrasts with
the 45 animals required to perform a similar study using a 252-
parameter FTA assay (Table 2). It should be noted that the
experiments using the two different methodologies are not exactly
congruent, with the replicates in the 2-parameter assay being
inter-animal and those in the 252-parameter assay being intra-
animal; it is also unlikely that the experiment would be practical
with a 2-parameter assay in that comparisons between vaccination
strategies performed in different experiments would not be ideal.
Nevertheless, the FTA assay is a significant reduction and
refinement of existing techniques that allows for potentially
dramatic reduction in animal numbers when using in vivo T-cell
assays.
Discussion
The FTA is a unique assay that allows the simultaneous
measurement of CTL killing and TH activity against numerous
target cells pulsed with a broad concentration range of several
different MHC-I/II binding peptides in vivo. The versatility of this
Figure 1. Schematic representation of a 252-parameter FTA assay. Splenocytes from mice were labeled with combinations of CTV (0 nM,
350 nM, 1295 nM, 4792 nM, 17729 nM and 65595 nM), CFSE (0 nM, 79 nM, 315 nM, 1106 nM 3859nm, 13505nm and 47269 nM) and CPD (0 nM,
106 nM, 690 nM, 2738 nM, 10262 nM and 38506 nM) to generate 252 discernable cell clusters. Cell clusters were pulsed with MHC-binding peptides
(as outlined in Figure 3) to generate a panel of 42 peptide pulsed clusters and this repeated 6 times to generate 6 intra-animal repeats (i.e., 252 target
cell clusters in total). Target cells were also labeled with DiI for discrimination from host splenocytes (not shown). (a) FTA cells were injected i.v. into
host mice that had 6 days earlier been vaccinated with VV-HIV or left unvaccinated as a control. 18 hr after FTA injection, splenocytes were collected
and target cells delineated from host splenocytes by DiI label using flow cytometry (not shown). (b) 2D plots of the fluorescence intensities of a panel
of one replicate of the 42 peptide-pulsed clusters from the unvaccinated and vaccinated animals and an associated histogram analysis of clusters
pulsed with titrations of the F2L CTL epitope, revealing killing in vaccinated animals. (c) An example of histogram analysis of the FTA T helper assay,
with B220+ FTA cells pulsed with the Gag Th TH cell epitope being assessed for CD69 up-regulation from the vaccinated animal compared to those
from the unvaccinated animal.
doi:10.1371/journal.pone.0105366.g001
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Figure 2. The FTA assay can measure magnitude, functional avidity and epitope variant cross-reactivity of CTL responses in vivo. Six
BALB/c mice were vaccinated with 56106 PFU VV Western Reserve i.p. A FTA was constructed using mouse splenocytes and comprised of fluorescent
target cells pulsed with 6 different concentrations of the MHC-I binding peptides F2L, F2L mut, A52R, and HIV neg (as a negative control). FTA target
cells were injected i.v. into infected mice 6 days post vaccination and after 18 hr in vivo % specific killing calculated for FTA target cells from harvested
spleens. a) In vivo killing responses from six infected animals. b) Summary of responses from all mice with means of % specific killing and standard
error of mean. c) Mean area under curve (AUC) measurements from % specific killing response curves and associated standard error of means. d)
Mean effective concentration of peptides used to pulse target cells that generated half maximal responses (EC50) and associated standard error of
means and P values.
doi:10.1371/journal.pone.0105366.g002
Table 1. HIV-1 pox virus vaccination regimes used in this study.
PRIME VACCINATION
BOOST VACCINATION 1 Nil 2 i.n. FPV 3 i.m. FPV 4 i.n. VV 5 i.m. VV
6 i.n. FPV 7 i.n. FPV 8 i.m. FPV 9 i.n. VV 10 i.m. VV
i.n. FPV i.n. FPV i.n. FPV i.n. FPV
11 i.m. FPV 12 i.n. FPV 13 i.m. FPV 14 i.n. VV 15 i.m. VV
i.m. FPV i.m. FPV i.m. FPV i.m. FPV
16 i.n. VV 17 i.n. FPV 18 i.m. FPV 19 i.n. VV 20 i.m. VV
i.n. VV i.n. VV i.n. VV i.n. VV
21 i.m. VV 22 i.n. FPV 23 i.m. FPV 24 i.n. VV 25 i.m. VV
i.m. VV i.m. VV i.m. VV i.m. VV
24 different vaccination regimes were included based on all combinations of FPV-HIV and VV-HIV administered either i.n. or i.m. in a prime-boost format. A control naı¨ve
animal receiving no vaccination (Nil) was also included.
doi:10.1371/journal.pone.0105366.t001
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Figure 3. High throughput screening of HIV-1 poxvirus vaccination regimes for high magnitude, high functional avidity and high
epitope variant cross-reactive T cell responses in vivo. Mice were vaccinated with 24 different vaccine regimes based on all combinations of
FPV-HIV and VV-HIV administered either i.n. or i.m. in a prime-boost strategy as outlined in Table 1. Mice were vaccinated with 56106 PFU of each
vaccine and booster vaccinations were given 2 weeks after the priming vaccination. T cell responses were assessed using a 252-parameter FTA
Use of the FTA Assay to Assess the Efficacy of HIV-1 Vaccines
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assay overcomes many of the limitations associated with other
techniques for measuring CTL killing and T cell mediated B cell
activation. For example, previously developed in vivo CTL killing
assays [8–10,17] are only able to measure the magnitude of the
killing response in a single animal without providing any detailed
measurements on functional avidity and epitope variant cross-
comprised of fluorescent target cells pulsed with 6 concentrations of the MHC-I binding peptides F2L, F2L mut, HIV Gag, HIV Gag mut, HIV Pol and
HIV Env, and the MHC-II binding peptide Gag TH. FTA target cells were injected i.v. into vaccinated mice 6 days post vaccination and responses
assessed after 18 hr in vivo using harvested spleens. % specific killing and TH cell activity was calculated as described in the Materials and Methods. a)
Cumulative magnitude of T cell responses as AUC was plotted as a heat map depicting the range of highest (darkest colour) to lowest (lightest
colour) TH cell (upper panel) or CTL (lower panels) responses. b) AUC heat maps of responses to the three HIV Gag epitopes. c) EC50 values of
responses to the three HIV Gag epitopes. Values are only shown where EC50 values were calculable as described in the Materials and Methods. AUC
and EC50 values are depicted as means from 6 intra-animal replicates. The results are representative of three independent experiments
doi:10.1371/journal.pone.0105366.g003
Figure 4. i.n.FPV-HIV/i.m.VV-HIV prime-boost vaccination improves the magnitude, functional avidity and epitope variant cross-
reactivity of T-cell responses compared to prime or boost vaccinations alone. Mice were vaccinated i.n. with FPV-HIV and/or i.m. VV-HIV.
Mice were vaccinated with 56106 PFU of each pox virus vaccine. Booster vaccinations were given 2 weeks post the previous vaccination. T-cell
responses were assessed using 252-parameter FTAs as in Figure 3. a) % specific killing of FTA cells in vivo by CTL and b) TH cell activity induced by
prime, boost, and prime-boost vaccination regimes, showing all 6 intra-animal replicate responses (upper panels) and means and standard error of
means (lower panels) to the various CTL epitopes. b) Mean and standard error of means from a). AUC and EC50 values of: c) CTL responses and: d) TH
cell responses. Values are only shown where EC50 values were calculable as described in the Methods. AUC and EC50 values are depicted as means
from 5 intra-animal replicates. The results are representative of seven independent experiments.
doi:10.1371/journal.pone.0105366.g004
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reactivity. In vitro assays that measure T cell activity/avidity, such
as the 51Cr-release assays, multi-parameter intracellular cytokine
staining assays and ELISpot peptide dilution assays, typically
require ex vivo stimulation of host effector T cells which can result
in changes in functional avidity at a population level, due to
preferential outgrowth of high avidity effector T cells [18]. Thus,
the FTA assay is an in vivo assay with an excellent capacity to
measure multiple parameters of T cell responses in a single animal.
The versatility of the FTA assay allowed the comprehensive
screening of T cell responses generated from 24 different
vaccination regimes against 7 distinct viral epitopes, which
included HIV epitopes (Gag, Gag Th, Gag mut, Pol and Env)
as well VV epitopes (F2L and F2L mut). From this analysis,
heterologous prime-boost vaccination regimes, particularly those
with FPV-HIV administered as the priming and VV-HIV
administered as the booster vaccination, were found to be the
most effective strategy in generating high magnitude CTL
responses of high functional avidity and high epitope variant
cross-reactivity. These results further substantiate our previous
studies showing that amongst numerous prime-boost vaccination
regimes involving the use of recombinant DNA, FPV-HIV and
VV-HIV, the FPV-HIV/VV-HIV vaccination regime was the
most effective in generating both high magnitude and high avidity
HIV Gag-specific CD8+ T cell responses [13,15,16]. The
synergistic improvement in responses to the HIV Gag epitopes
seen in these heterologous prime-boost strategies may reflect the
establishment of enhanced competition of HIV Gag epitopes for
generating T cell responses over that of the dominant vector
epitopes [19]. Since the immune system is not exposed twice to the
dominant vector epitopes in these vaccine strategies, the vector
epitope-induced responses are less able to compete with the
memory responses generated against the HIV Gag epitopes post
booster vaccination. This may then result in selective enrichment
of high avidity HIV Gag-specific T cells [20]. These finding once
again demonstrate that vector combination plays a critical role in
vaccine efficacy. Interestingly, the FTA assay did not distinguish
any vaccination route dependency with the FPV-HIV/VV-HIV
vaccination strategy with regards to functional avidity profiles of
CTLs in the systemic (splenic) compartment. Mucosal vaccination
regimes have previously been shown to induce CTLs of higher
avidity, particularly at mucosal sites, with greater protective
immunity compared to the purely systemic delivery of vaccines
[15,21,22]. Thus, it will be of great interest to use the FTA assay to
assess how the different vaccine administration routes can alter the
quality of mucosal T cell immunity. One caveat of the FTA assay
in its current form is that it relies on target cells that are pulsed
with known CTL and TH epitopes rather than target cells that
naturally present these epitopes from infecting pathogens. It will,
therefore, be important to relate T cell responses measured with
the FTA assay to microbe challenge studies or devise ways in
which to use infected targets in the assay. In addition, since a large
number of targets can be generated by the FTA assay, there is
potential to use the method in screening MHC-binding peptide
libraries for epitopes that are recognized by responding T cells,
which can then be used in subsequent vaccine screening assay.
Recent studies indicate epitope variant cross-reactive T cell
responses are of importance when dealing with diseases like HIV-
1. Broad epitope variant cross-reactivity of CTLs has been
observed in HIV patients who are ‘elite controllers’ [7]. Similar
findings have been reported in hepatitis C virus patients, where
clearance of the virus was associated with increased CTL epitope
variant cross-reactivity and heightened functional avidity [18].
Interestingly, the FPV-HIV/VV-HIV vaccination regime that
induced high avidity CTL also was able to generate strong CTL
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responses to the mutant Gag epitope, suggesting that high avidity
CTL clones have greater capacity to recognize Gag escape mutant
variants. In the context of an effective HIV-vaccine, recognition of
Gag escape variants are of high significance [23]. Collectively, the
current study demonstrates that FPV-HIV/VV-HIV heterologous
prime-boost vaccination regimes have the hallmarks of an
efficacious vaccination strategy that could induce good protective
efficacy.
In conclusion, by using the FTA assay we have extensively
evaluated a combination of vectors expressing HIV epitopes for
their ability to generate high quality T cell responses in vivo. We
have found that the magnitude, functional avidity and epitope
variant cross-reactivity of CTLs is dependent on the vaccine vector
combination and out of the 24 pox virus vaccine combinations
tested, FPV-HIV/VV-HIV vaccination strategies induced the best
immune outcomes. Overall, our data suggest that the FTA assay is
an extremely valuable tool that can be used for large scale
screening of vaccine combinations for pre-clinical testing in a more
ethical and cost effective manner.
Material and Methods
Mice and Ethics statement
Male 6-10 week old BALB/c mice were purchased from the
Australian Phenomics Facility, Australian National University
(ANU). All animals were maintained and experiments were
performed in accordance with the Australian NHMRC guidelines
within the Australian Code of Practice for the Care and Use of
Animals for Scientific Purposes and in accordance with guidelines
approved by the Australian National University Animal Experi-
mentation and Ethics Committee (AEEC). This study was
approved by the AEEC and listed under ANU ethics protocol
number A2011/018. All animals were monitored daily, infected
mice were scored for signs of illness and weight loss and when
showing signs of undue stress were ethically sacrificed by cervical
dislocation in accordance with the above AEEC approved
protocols.
Peptides
Peptides included the MHC-I-binding peptides, SPYAAGYDL
(F2L, an Ld-restricted vaccinia virus (VV) epitope), SPGAAGYDL
(F2L mut, a modified vaccinia Ankara virus epitope homologous
to F2L), AMQMLKETI (HIV Gag, an immunodominant Kd-
restricted HIV Gag epitope [24]), AMQMLKDTI (HIV Gag mut,
a HIV Gag subtype C variant of HIV Gag [25]), VGPTPVNII
(HIV Pol, a Dd-restricted HIV pol epitope [26]), RGPGRAFVTI
(HIV envelop (Env), a Dd-restricted HIV env epitope [27], and
AMQMLEKTI (HIV neg, a modified HIV gag epitope that serves
as a negative control [28]) and the MHC-II-binding peptide
PVGEIYKRWIILGLN (Gag TH, a H-2
d-restricted HIV Gag
epitope [24]). Peptides were synthesized at the Biomolecular
Resource Facility, John Curtin School of Medical Research, ANU.
Vaccines
The recombinant FPV encoding HIV AE clade Gag, Pol and
Env (FPV-HIV - 117a); recombinant VV encoding HIV AE clade
Gag and Pol (VV-HIV - 336); recombinant VV encoding HIV AE
clade Env (VV-HIV - 337); and wild-type VV Western Reserve
were prepared as described previously [14,29].
Immunization and FTA target cell injection
Host mice were immunized with 56106 PFU of FPV-HIV -
117a, a combination of 2.56106 PFU of VV-HIV - 336 and
2.56106 VV-HIV - 337 or 56106 PFU wild-type VV Western
Reserve. All pox-viral vector immunizations were performed via
the intranasal (i.n.) or intramuscular (i.m.) routes as described in
Table 1 under mild isoflurane anaesthesia. Immediately prior to
delivery the viruses were diluted in phosphate buffered saline (PBS)
and sonicated 20–30 s to obtain an homogeneous viral suspension,
intranasal FPV was given in a final volume of 20–25 ml and i.m.
VV were delivered, 50 ml per quadriceps. [14]. The FTAs were
injected i.v. into host mice following 6 days post immunization at a
total cell number of 56107 and left in vivo for 18 hr before FTA
cells were assayed for target cell help and killing.
FTA preparation
CFSE, CTV and CPD dye labeling and construction of FTAs
was as described previously [11,30]. Briefly, 2 ml aliquots of equal
numbers of splenocytes in 20 uC RPMI-1640 media (Invitrogen)
supplemented with 10% fetal calf serum (FCS), were labeled with
0–65595 nM of CTV for 5 min. Cells were then split equally in up
to 7 aliquots and labeled with 0–47269 nM of CFSE in a final
volume of 1 ml of RPMI-1640 supplemented with 10% FCS for
5 min. After washing the cells once, they were then pulsed with 0–
400 mM MHC-I or MHC-II-binding peptide epitopes for 1 hr at
37uC. To remove excess peptide, cells were sedimented through a
3.5 ml FCS cushion at 4uC, then washed with 10 ml of RPMI-
1640 supplemented with 10% FCS at 4uC and cells then pooled
together. To generate intra-animal replicates the pooled cell
population was split into six 2 ml aliquots and labeled with 0–
38500 nM of CPD, washed twice and all aliquots pooled. Cells
were washed twice with 10 ml of RPMI 1640 supplemented with
5% FCS, pooled and washed once more. To allow the FTA to be
detected in syngeneic BALB/c host mice a 4th dye, DiI, was used
to label all targets cells for their detection in vivo. DiI (Invitrogen)
was used at 14 mM to label cells as described by the manufacturer.
The FTA was then counted and resuspended at up to
256107 cells/mL ready for injection.
Antibody labeling of cells
Splenocytes from mice were labeled with antibodies to delineate
cell populations and included anti-CD4-PE-Cy7, anti-CD4-
Brilliant Violet 605, anti-CD4-Alexa Fluor 700, anti-CD8a-
APC-eFluor 780, anti-B220-PerCP-Cy5.5, anti-B220-Alexa Fluor
700, anti-CD69-PerCp-Cy5.5, and anti-CD69-Brilliant Violet
605, purchased from either BD Bioscience, eBioscience or
Biolegend. Cell viability was assessed with the dye Hoechst
33258 (1 mg/ml, Calbiochem-Behring Corp.). Cells were labeled
with antibodies and Hoechst 33258 for 20–30 min on ice and
washed twice as previously described [31].
Flow cytometry of cells
For flow cytometry analysis, cells were first filtered through a
70 mM mesh to remove cell clumps. Flow cytometry was
performed using a Fortessa flow cytometer (Becton Dickinson).
Post acquisition gating was used to analyze cell subsets using
FlowJo software (Tree Star, OR). The flow cytometer underwent
periodic quality control assessment using eight channel fluorescent
beads throughout the period of experimentation.
% Specific killing and T cell help calculations
The % specific killing and T cell help was assessed as previously
described [11,12,28]. Briefly, for the CTL responses, the number
of cells in each FTA cell cluster was calculated using FlowJo
software and the % specific killing values were then generated
using the following formula:
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T cell help was assessed on the basis of CD69 upregulation on
FTA B cell by antibody labeling and flow cytometry. Expression of
CD69 in the Figures was calculated by subtracting the activation
marker geometric mean fluorescence intensity (GMFI) on FTA B
cells from naı¨ve mice from that on FTA B cells from the
vaccinated mice.
Statistical analysis
Area under the curve (AUC), EC50 (peptide concentrations
giving half maximal response) and the Mann-Whitney nonpara-
metric two-tailed test was performed using GraphPad Prism
Software 5.0f (Graphpad Inc).
Supporting Information
Figure S1 Raw data from screening of HIV-1 pox virus
vaccination regimes for high magnitude, high-functional
avidity and high epitope variant cross-reactive T cell
responses in vivo. Mice were vaccinated with 24 different
vaccination regimes as in Figure 3. T cell responses were assessed
using a 252-parameter FTAs comprised of fluorescent target cells
pulsed with 6 different concentrations of the MHC-I binding
peptides F2L, F2L mut, HIV Gag, HIV Gag mut, HIV Pol and
HIV Env, and the MHC-II binding peptide Gag Th and this
repeated 6 times to generate 6 intra-animal replicates. % specific
killing data from all intra-animal replicates (a) and associated
means and standard error of means (b). TH cell activity data from
all intra-animal replicates (c) and associated means and standard
error of means (d). e) Cumulative magnitude of T cell responses as
AUC plotted as a heat map depicting the mean CTL (upper
panels) or mean TH cell (lower panel) responses from 6 intra-
animal replicates at each concentration of epitope used to pulse
target cells (in mM).
(DOC)
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